Elektrofi

Executive Summary

Elektrofi is a Boston-based biopharmaceutical formulation technology company dedicated to transforming biologic drug delivery. Founded in 2018, the company addresses a critical pain point in the treatment of chronic diseases: the burden of frequent intravenous (IV) infusions. By enabling high-concentration, low-volume subcutaneous injections, Elektrofi's platform allows biologic therapies to be self-administered at home, improving patient convenience and adherence while reducing healthcare costs. The company operates as a partner to biopharma firms, reformulating existing or pipeline biologics into a more patient-friendly subcutaneous format. This approach de-risks development for partners and accelerates time-to-market for improved versions of blockbuster drugs. Elektrofi has not yet disclosed public funding or pipeline details, but its technology has broad applicability across therapeutic areas such as oncology, immunology, and rare diseases. The company's value proposition is strengthened by the growing demand for patient-centric delivery and the multibillion-dollar market for biologic drugs. As the biologic market expands and patents expire, partners seek differentiation through improved delivery. Elektrofi's platform could enable line extensions and lifecycle management for major biologics. The key risks include formulation challenges for certain molecules and competition from other drug delivery platforms. Overall, Elektrofi is positioned to capitalize on the shift toward subcutaneous self-administration in biologics.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a Major Biopharma Partnership60% success
• Q4 2026Series A or B Funding Round Closure50% success
• Q1 2027First Clinical Proof-of-Concept Data for a Partnered Program40% success